Ubs Group Ag Seres Therapeutics, Inc. Transaction History
Ubs Group Ag
- $400 Billion
- Q2 2024
A detailed history of Ubs Group Ag transactions in Seres Therapeutics, Inc. stock. As of the latest transaction made, Ubs Group Ag holds 200,726 shares of MCRB stock, worth $164,595. This represents 0.0% of its overall portfolio holdings.
Number of Shares
200,726
Previous 105,966
89.42%
Holding current value
$164,595
Previous $81,000
77.78%
% of portfolio
0.0%
Previous 0.0%
Shares
29 transactions
Others Institutions Holding MCRB
# of Institutions
93Shares Held
46.7MCall Options Held
119KPut Options Held
466K-
Flagship Pioneering Inc. Cambridge, MA23.1MShares$19 Million1.99% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.29MShares$5.15 Million0.0% of portfolio
-
Tang Capital Management LLC San Diego, CA2.41MShares$1.97 Million0.21% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny1.78MShares$1.46 Million0.0% of portfolio
-
Black Rock Inc. New York, NY1.76MShares$1.44 Million0.0% of portfolio
About Seres Therapeutics, Inc.
- Ticker MCRB
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 124,072,000
- Market Cap $102M
- Description
- Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. The company's lead product candidate is the SER-109, an oral microbiome therapeutic candidate that has completed Phase III clinical trial for the ...